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Acquired heart disease in Low and Middle Income Countries 
 
Introduction 
In low and middle-income countries (LMIC) the child health focus has typically been on the high 
burden of communicable diseases. While implementation of the millennium development goals has 
seen the under-five mortality decline by more than half between 1990 and 2015, further reductions 
require more focus on neglected and non-communicable diseases1. In recent years there has been 
increasing interest in the burden associated with congenital and acquired heart disease. 
There are little reliable data concerning the spectrum and prevalence of paediatric cardiac disease in 
LMIC, but enough to know that the burden is considerable with patients typically presenting with 
advanced disease2. A small number of studies have characterised the spectrum of acquired heart 
disease in specific populations in LMIC. One study in Malawi found that acquired heart disease 
accounted for 44.4% of pathology presenting to an urban paediatric cardiology clinic, predominantly 
rheumatic heart disease and dilated cardiomyopathy3. Multiple studies have confirmed RHD as the 
leading cause of heart disease in children in developing countries4. Indeed, the burden of disease is 
significant in comparison with other better studied and funded diseases in LMIC. For example 314, 
000 people die per annum with RHD, which is similar to the number of deaths due to neonatal 
sepsis (351,000) or as a result of congenital heart disease (303,000)5. It has been estimated that 
RHD has a mortality about 50% of malaria, yet receives only 0.07% of global health funding6. 
Studies In endemic parts of Africa and Asia have shown that HIV and TB are a significant cause of 
childhood cardiac disease while endomyocardial fibrosis is important in specific, high prevalence 
areas of Africa, Asia and South America7,8. 
In this review, therefore, we will concentrate on the significant causes of acquired heart disease in 
children in LMIC; rheumatic heart disease, tropical endomyocardial fibrosis, dilated cardiomyopathy 
(including HIV) and tuberculous pericarditis. 
Rheumatic Heart Disease 
While rheumatic heart disease (RHD) ceased to be a public health concern in most developed 
countries decades ago, it remains the largest cardiac cause of morbidity and mortality in children, 
adolescents and young adults in LMIC worldwide. Most recent figures estimate that there are nearly 
33 million people with rheumatic heart disease globally, accounting for around 275, 000 deaths per 
year 9. A recent systematic review and meta-analysis of population based studies across Oceania, 
Asia, Africa, Latin America and Europe found evidence of clinically manifest disease in 2.7 per 1000 
children and clinically silent disease in 21 per 1000 children in endemic countries10. 
The development of RHD is associated with severe or multiple episodes of acute rheumatic fever 
(ARF) which peak between the ages of five and fourteen11. Group A streptococcal infection of the 
pharynx leads to an autoimmune response characterized by various combinations of fever, joint pain 
and swelling, carditis, chorea and skin manifestations. Clinical diagnosis is guided by the Jones 
criteria, updated in 2015, and streptococcal serology which is often not available in LMIC11. The 
development of chronic cardiac complications is highly preventable with the use of antibiotics as 
primary and secondary prophylaxis11. Without effective treatment of repeated episodes, the 
development of cross-reactive immune complexes and inflammation of the heart valves and 
myocardium results in permanent valvular damage and the development of RHD (Figure 1). Valvular 
manifestations are typically mitral and/or aortic regurgitation with stenosis in long-standing cases, 
leading to the development of cardiac failure and increased risk of embolic stroke, endocarditis and 
atrial fibrillation11. Barriers to the implementation of primary and secondary prevention can include 
limited access to primary care, lack of healthcare workers, expense of microbiological diagnosis or 
echocardiography, poor community awareness and lack of recognition of ARF by clinicians. For 
example, in one cohort study of 309 newly diagnosed patients with RHD in Uganda none had a 
confirmed history or ARF12.  
Successful management of RHD hinges on secondary penicillin prophylaxis to prevent disease 
progression, specialist review and serial cardiac imaging, appropriate prescription and monitoring of 
anticoagulation and timely referral for cardiac surgery11. Unfortunately, in many LMIC access to 
these services is poor and many patients present late in the disease course with established RHD, 
advanced cardiac failure, embolic stroke, infective endocarditis or symptomatic arrhythmias11. The 
REMEDY study, an international hospital based registry of 3,343 patients with symptomatic RHD in 
12 African countries, India and Yemen, has highlighted the ongoing challenges in the management of 
RHD in LMIC9,13. Only 54.8% of patients were on secondary penicillin prophylaxis. Appropriate use of 
oral anticoagulation was variable, with low rates even amongst patients with mitral stenosis or 
established left atrial thrombus. Monitoring of warfarin prescription provided challenges, with 12.2% 
having no INR monitoring and 34% monitored less than 3 times in 6 months. Only 10.3% of patients 
requiring surgery or percutaneous procedures received intervention, most of whom were in upper-
middle-income countries9. At two year follow up 16.9% of the cohort had died at a median age of 
28.79. 
Earlier detection and management of ARF and RHD in LMIC is clearly critical to reducing the 
burden of disease. Multiple studies using portable echocardiography in school-aged children have 
detected a high prevalence of latent, pre-clinical disease, raising the possibility of successful 
secondary prophylaxis in these children before complications occur11. One study in Fiji showed that 
nurse led echocardiographic screening had good sensitivity and specificity in detecting mitral 
regurgitation in RHD14. However it remains unclear which children with latent disease will benefit 
from prophylaxis as a proportion of those with borderline disease improve to normal after medium-
term follow-up15. Further large-scale trails are required before recommending the implementation 
of a potentially very costly and skill intensive intervention. Targeted screening of index cases may 
be a useful approach to identify those at risk of developing symptomatic disease16. 
The findings of REMEDY reinforce the fact that RHD is a disease of poverty and social injustice. 
Those affected are predominantly young, largely unemployed and two thirds are female9. It is 
known that household overcrowding, rural location and under-nutrition are all associated with 
increased risk of ARF and RHD11. Education beyond primary school is associated with significantly 
decreased risk of mortality9. Encouragingly there has been a renewed interest in tackling RHD in 
recent years, with the World Heart Federation calling for a 25% reduction in premature mortality 
from RHD by 2025 and the Social Cluster of the Africa Union Commission laying out key priorities for 
tackling RHD in 201517. Central to these efforts will be development of robust surveillance 
programmes for RHD, increased access to primary and secondary prophylaxis and the establishment 
of cardiac surgical services in LMIC. Improvement of the social determinants of health in LMIC, by 
tackling living conditions and overcrowding, is an over-riding challenge in countries with high 
prevalence of RHD. 
After many years of research there is renewed hope of the development of an effective group A 
streptococcal vaccine to aid primary prevention of RHD. Challenges in development have included 
the plethora of group A streptococcal strains, the risk of immune reactivity to the vaccine and 
commercial viability18. 
Tropical endomyocardial fibrosis 
Endomyocardial fibrosis (EMF) is the most common cause of restrictive cardiomyopathy worldwide, 
characterised by deposition of fibrous tissue in the endomyocardium19. This neglected disease 
typically affects poor, rural populations in tropical LMIC, with geographically distinct pockets of high 
prevalence in Africa, Asia and South America. In contrast to rheumatic heart disease, the main 
challenges in managing EMF are a lack of knowledge of the origin and pathogenesis of the disease 
with no specific treatment or evidence based prevention strategies currently available19. 
Although first described in 1948, the pathogenesis of the disease remains unclear. Proposed, but 
unproven disease mechanisms include hypereosinophilia, infection, autoimmune, genetic, dietary 
and geochemical factors19. The occurrence of EMF in small numbers of people from Europe and 
North America after short stays in endemic regions supports the role of an infectious or other 
environmental cause, however no specific trigger has been identified19. Familial occurrence and high 
incidence among certain ethnic groups has indicated a genetic susceptibility to the disease19.  
Critically, EMF cannot be explained by a single cause in all areas where it has been reported. It is 
likely to be triggered by multiple independent environmental factors acting on individuals with a 
genetic predisposition19. 
An estimated 10 million people are affected by EMF worldwide although geographic distribution in 
affected countries is not uniform20. In endemic areas of Africa EMF is the second most common 
cause of admission for acquired heart disease (after rheumatic heart disease) and accounts for 20% 
of all cases of heart failure21. Few systematic studies of prevalence in the community exist, but a 
community based study in a rural area of Mozambique using portable echocardiography found 
evidence of EMF in 19.8% of the general population, and 28.1% of those aged 10-19 years22. 
Children and adolescents are predominantly affected, with over half of cases seen in the first decade 
of life21. 
If recognised, the initial clinical features of EMF are a febrile illness associated with pericarditis and 
eosinophilia, dyspnoea, itching and periorbital swelling19. This is followed by ventricular thrombosis 
affecting usually the apices and subvalvular apparatus which evolves to form endocardial fibrosis 
typical of the advanced stage of the disease. The resulting impedance of ventricular filling and valve 
distortion leads to restrictive physiology with atrioventricular regurgitation, and the typical 
appearance of small ventricles with severely dilated atria (Figure 2). Echocardiography is the 
mainstay of diagnosis8. The majority of patients present late with features of longstanding cardiac 
failure, clubbing, growth retardation, testicular atrophy, pubertal delay and cachexia. Marked ascites 
out of proportion to peripheral oedema is typical, leading some authors to hypothesise EMF to be a 
systemic syndrome with associated peritoneal inflammation19. Atrial fibrillation occurs in greater 
that 30% of cases, and other conduction abnormalities are common19. 
No specific treatment has been developed to treat EMF. Medical management is based on the 
symptomatic treatment of heart failure, arrhythmias and anticoagulation where indicated19. Short 
courses of steroids have been used to suppress eosinophilia in the acute phase of the disease, 
although there is a lack of evidence to support their use19. Surgical intervention has been shown to 
improve symptoms and improve survival in EMF, most commonly using targeted endocardial 
resection combined with valve repair or replacement23. However, access to cardiac surgery in 
endemic regions is extremely limited, with only a handful of sub-Saharan African countries having 
independent cardiac surgery programmes24. Research into surgical intervention is limited to a small 
number of studies in patients with advanced disease21. 
The prognosis of EMF remains extremely poor, with 75% of patients dying within 2 years of 
diagnosis19. Death is typically due to progressive heart failure, pulmonary embolism or fatal 
ventricular arrhythmia21. There is an urgent need for further research into the aetiology and 
mechanisms of the disease in order to develop effective treatment and prevention strategies. 
Dilated Cardiomyopathy 
In developed countries dilated cardiomyopathies (DCM) account for about half of all childhood heart 
transplants and population cohort studies have found an annual incidence of cardiomyopathy of up 
to 1.24 per 100,000 children under the age of ten25. Epidemiological data is lacking in developing 
countries, but the disease burden is thought to be significant given the association of 
cardiomyopathies with malnutrition and infectious disease26. One tertiary centre in Nigeria recorded 
cardiomyopathy in nearly 3% of children accessing cardiac services in South-west Nigeria27. A lack of 
specialist investigations poses significant problems to the diagnosis and management of paediatric 
DCM in LMIC. The cause in most children is not known. 
HIV associated cardiomyopathy is an important known cause. The Heart of Soweto study found that 
HIV associated DCM was the most common cardiac diagnosis amongst HIV positive patients28. In one 
Ugandan study, cardiac abnormalities were present in 50% of newly diagnosed HIV positive 
children29. Direct infection of myocytes with HIV triggering an autoimmune response is thought to 
underlie HIV cardiomyopathy, although nutritional deficiencies, and opportunistic infections are also 
implicated29. HIV cardiomyopathy is an indication to start anti-retroviral therapy, independent of 
CD4 count, and there is justification for routine echocardiography in HIV-positive children in order to 
identify pre-symptomatic cardiac disease. However in areas where early antiretroviral treatment is 
available, the incidence is falling. 
In Latin America, Chagas disease caused by Trypanosoma cruzi is known to be a significant infective 
cause of DCM. Although usually observed in chronic disease 10-20 years after initial infection, a 
recent epidemiological study of more than 3000 children in Mexico identified 14 children with pre-
symptomatic chagasic cardiomyopathy30. It is unclear if antiparasitic treatment improves the 
prognosis once the disease has developed31. 
β thalassemia is a common inherited blood disorder in the Indian sub-continent, south-east and 
central Asia, Southern China, Mediterranean, North Africa and the Middle East, characterised by 
severe anaemia requiring regular blood transfusions32. These children are at risk of Iron-overload 
related cardiomyopathy in LMIC. A public health review in 2008 estimated over 25000 annual 
births of transfusion dependent thalassemia worldwide, mostly in LMIC33. While only 11.7% of 
children who require transfusions receive them, those who do carry a significant risk of developing 
cardiac iron overload and cardiomyopathy with a subsequent rapid decrease in myocardial 
function and death33. This has been demonstrated in children under the age of 10 despite 
receiving chelation therapy34. The high cost of managing these patients presents a difficult 
challenge to health systems in LMIC. 
 
Tuberculous Pericarditis 
WHO figures in 2015 estimated that globally, 1 million children are infected with TB, predominantly 
in LMIC in Asia and Sub-Saharan Africa, accounting for more than 136,000 deaths each year35. TB is 
one of the most common causes of pericardial effusion in TB endemic countries, with approximately 
1-4% of children with TB developing pericarditis36. The HIV pandemic has dramatically changed the 
epidemiology, manifestation and treatment options for TB pericarditis. In one large study in South 
Africa, 83% of patients aged 15-29 undergoing pericardiocentesis for large pericardial effusions had 
TB, with over 50% of patients co-infected with HIV37. HIV predisposes patients to more disseminated 
disease, with increased risk of pericardial and myocardial involvement37,38. 
In children, TB pericardial disease has three main presentations: pericardial effusion (most 
common), constrictive pericarditis, and a combination known as effusive-constrictive disease. Most 
frequently, the pericardium is infiltrated from an infected contiguous subcarinal lymph node38. Once 
in the pericardium, an inflammatory process with granuloma formation results in the production of a 
fibrinous exudate37. 
Importantly, the clinical presentation is variable and often non-specific. However, given the poor 
availability and sensitivity of microbiological diagnosis in LMIC, the diagnosis is usually based on 
clinical signs alone. A high index of suspicion is required in endemic areas39. Children typically 
present with signs and symptoms of heart failure, including persistent cough, dyspnoea, chest pain 
and hepatomegaly in addition to fever, night sweats and failure to thrive38. Chest radiography may 
show cardiomegaly with a globular silhouette, while echocardiography can confirm the presence of 
effusions, often associated with fibrinous threads and a “bread and butter” appearance of the 
visceral pericardium and may identify associated mediastinal lymphadenopathy38. Valvular disease 
is not a typical feature of TB pericarditis however the myocardium is often affected adding to the 
complexity of the disease. The following features of pericardial fluid suggest TB: a predominantly 
lymphocytic cell count, elevated protein and LDH level and glucose 3.0–5.5 mmol/L are suggestive 
but not diagnostic of TB38. 
Specific research in the management of childhood tuberculous pericarditis is lacking, and adult 
management regimens are followed 40. A typical approach is pericardiocentesis if there is evidence 
of tamponade, followed by an initial regimen of rifampicin, isoniazid, pyrazinamide and ethambutol 
for at least two months followed by isoniazid and rifampicin for a further four months.  Pericardial 
TB management in children is complicated by the lack of suitable formulations of medications for 
the first years of life. The multicentre IMPI trial showed that the use of adjunctive high dose steroids 
reduced the incidence of constrictive pericarditis and frequency of hospitalisation in adults, but was 
associated with an increased risk of malignancy in patients with HIV41. No similar study in children 
exists. Surgical resection of the pericardium is indicated in patients with persistent constrictive 
symptoms following anti-TB chemotherapy37. 
Conclusions 
The burden of illness associated with acquired cardiac disease in children in LMIC is significant and 
may be equivalent to that of congenital heart disease. Rheumatic heart disease, endomyocardial 
fibrosis, cardiomyopathy (including HIV cardiomyopathy) and TB are the most important causes. All 
are associated with poverty with the neediest children having the least access to care. The 
associated mortality and morbidity is high. While detailed analysis of the cost burden of and 
funding for these diseases is beyond the scope of this review there is a clear disparity between the 
burden of disease and current research. There is an urgent need to improve cardiac care in LMIC, 
particularly in sub-Saharan Africa and parts of South-East Asia where the burden is highest. 
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Captions for figures 
Figure 1: Parasternal long axis view echocardiogram demonstrating dilated left atrium, and 'hockey 
stick' deformity of stenosed mitral valve seen in rheumatic heart disease (LA. Left atrium; LV, left 
ventricle; AV, aortic valve; AMVL, anterior mitral valve leaflet) 
 
Figure 2: Subcostal 4 chamber view echocardiogram demonstrating a hugely dilated right atrium 
(outlined with dashed white line) and obliteration of the right ventricle in endomyocardial fibrosis 
(RA, right atrium; RV, right ventricle; LA, left atrium; LV, left ventricle) 
 
